Novonesis Yönetim

Ester Baiget'un ücretlendirmesi Novonesis'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	€283m
Mar 31 2024	n/a	n/a	€332m
Dec 31 2023	€4m	€1m	€406m
Sep 30 2023	n/a	n/a	€430m
Jun 30 2023	n/a	n/a	€460m
Mar 31 2023	n/a	n/a	€487m
Dec 31 2022	€3m	€1m	€494m
Sep 30 2022	n/a	n/a	€460m
Jun 30 2022	n/a	n/a	€418m
Mar 31 2022	n/a	n/a	€416m
Dec 31 2021	€3m	€1m	€423m
Sep 30 2021	n/a	n/a	€427m
Jun 30 2021	n/a	n/a	€409m
Mar 31 2021	n/a	n/a	€389m
Dec 31 2020	€3m	€927k	€380m

Tazminat ve Piyasa: Ester's total compensation ($USD4.23M) is about average for companies of similar size in the Danish market ($USD3.61M).

Tazminat ve Kazançlar: Ester's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.

CEO

Ester Baiget (53 yo)

4.8yrs

Görev süresi

€3,903,958

Tazminat

Ms. Ester Baiget serves as Chief Executive Officer and President of Novozymes A/S since joining on February 1, 2020. She serves as Member of Supervisory Board at Akzo Nobel N.V. since 2022. She served as t...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Ester Baiget	President & CEO	4.8yrs	€3.90m	Veri yok
Rainer Lehmann	Executive VP & CFO	less than a year	€858.60k	Veri yok
Anders Lund	Chief Operating Officer	less than a year	€1.03m	Veri yok
Claus Fuglsang	Chief Scientific Officer	4.2yrs	Veri yok	Veri yok
Tobias Bjorklund	Head of Investor Relations	no data	Veri yok	Veri yok
Tue Micheelsen	Vice President of Global Sales & Marketing	no data	Veri yok	Veri yok
Morten Rasmussen	Executive Vice President of People & Stakeholder Relations	3.6yrs	Veri yok	Veri yok
Tina Fano	Executive Vice President of Planetary Health Biosolutions	8.8yrs	€1.02m	Veri yok
Amy Byrick	Executive Vice President of Human Health Biosolutions	3.6yrs	Veri yok	Veri yok
Henrik Nielsen	Executive Vice President of Strategy & Integration	less than a year	Veri yok	Veri yok
Jacob Paulsen	Executive Vice President of Food & Beverage Biosolutions	less than a year	Veri yok	Veri yok
Peter Rosholm	Chief Executive Officer of Albumedix	8.8yrs	Veri yok	Veri yok

3.6yrs

Ortalama Görev Süresi

50yo

Ortalama Yaş

Deneyimli Yönetim: NSIS B's management team is considered experienced (3.6 years average tenure).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Jesper Brandgaard	Vice Chair of the Board	less than a year	Veri yok	Veri yok
Cornelis de Jong	Independent Chairman	4.8yrs	€239.07k	0.0011% DKK 2.2m
Kim Stratton	Independent Director	7.8yrs	€173.33k	Veri yok
Kasim Kutay	Director	7.8yrs	€107.73k	0.00023% DKK 461.7k
Heine Dalsgaard	Director	4.8yrs	€143.55k	0.00065% DKK 1.3m
Lise Kaae	Director	less than a year	Veri yok	Veri yok
Lena Holskov	Employee Representative Director	11.8yrs	€66.91k	Veri yok
Anders Knudsen	Employee Representative Director	11.8yrs	€71.77k	Veri yok
Sharon James	Independent Director	4.8yrs	€143.55k	Veri yok
Preben Nielsen	Employee Representative Director	3.7yrs	€107.73k	0.000090% DKK 180.7k
Jens Obro	Employee Representative Director	3.7yrs	€71.77k	0.00012% DKK 240.9k
Morten Otto Sommer	Independent Director	2.7yrs	€137.51k	0.00022% DKK 441.7k

4.8yrs

Ortalama Görev Süresi

58.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: NSIS B's board of directors are considered experienced (4.8 years average tenure).

Novonesis Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Novonesis A/S Announces Board Changes

Novozymes A/S Announces Board Appointments

Novozymes A/S and Chr. Hansen Announce Executive Leadership Team and Organizational Structure

Novozymes A/S Announces Change to the Executive Leadership Team

Independent Chairman recently bought kr.1.0m worth of stock

Novozymes A/S Announces Jørgen Buhl Rasmussen Decides Not to Seek Re-Election as Member of its Board of Directors

Recent updates

Novonesis A/S Announces Board Changes

Consensus EPS estimates fall by 12%

Consensus EPS estimates increase by 11%

Consensus EPS estimates fall by 20%

First half 2024 earnings released: EPS: €0.14 (vs €0.67 in 1H 2023)

Novonesis Approves Interim Dividend for 2024, Payable on September 3, 2024

Consensus EPS estimates increase by 13%, revenue downgraded

Novonesis Provides Sales Guidance for the Year 2024

Novozymes A/S Approves Dividend for the Last Four Months Ended December 31, 2023

Upcoming dividend of kr.2.00 per share

Novozymes A/S Proposes Dividend for the Last Four Months Ended December 31, 2023

Novonesis Provides Earnings Guidance for the Year 2024

Novonesis to Unveil Fit-for-Food Mood-Support Probiotic at Natural Product Expo West

Novozymes A/S Announces Board Appointments

Consensus EPS estimates increase by 13%

Consensus EPS estimates increase by 13%

Consensus EPS estimates increase by 13%

Consensus EPS estimates increase by 13%

Consensus EPS estimates increase by 13%

Novozymes A/S to Report First Half, 2024 Results on Aug 28, 2024

Consensus EPS estimates increase by 14%

Full year 2023 earnings: Revenues in line with analyst expectations

New major risk - Shareholder dilution

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S to Report Fiscal Year 2023 Final Results on Apr 08, 2024

Novozymes Launches Quara(R) Lowp for Renewable Diesel Feedstock Pre-T Treatment

Novozymes Launches ProSilience™ HU58

Third quarter 2023 earnings: Revenues exceed analyst expectations

Novozymes A/S Approves Interim Dividend, Payable on October 17, 2023

Novozymes A/S and Chr. Hansen Announce Executive Leadership Team and Organizational Structure

These 4 Measures Indicate That Novozymes (CPH:NZYM B) Is Using Debt Reasonably Well

An Intrinsic Calculation For Novozymes A/S (CPH:NZYM B) Suggests It's 22% Undervalued

Now 21% undervalued after recent price drop

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Novozymes (CPH:NZYM B) Might Be Having Difficulty Using Its Capital Effectively

Does Novozymes (CPH:NZYM B) Have A Healthy Balance Sheet?

Novozymes A/S Announces Change to the Executive Leadership Team

Calculating The Fair Value Of Novozymes A/S (CPH:NZYM B)

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Novozymes (CPH:NZYM B) Might Be Having Difficulty Using Its Capital Effectively

Does Novozymes (CPH:NZYM B) Have A Healthy Balance Sheet?

Is Now The Time To Put Novozymes (CPH:NZYM B) On Your Watchlist?

Upcoming dividend of kr.6.00 per share at 1.8% yield

Novozymes' (CPH:NZYM B) Profits Appear To Have Quality Issues

Independent Chairman recently bought kr.1.0m worth of stock

Calculating The Fair Value Of Novozymes A/S (CPH:NZYM B)

Novozymes A/S Provides Earnings Guidance for the Year 2023

Full year 2022 earnings: Revenues in line with analyst expectations

Novozymes A/S Announces Jørgen Buhl Rasmussen Decides Not to Seek Re-Election as Member of its Board of Directors

Is Novozymes (CPH:NZYM B) Using Too Much Debt?

Investor sentiment deteriorated over the past week

Novozymes A/S (CPSE:NZYM B) agreed to acquire Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S (CPSE:NZYM B) agreed to acquire Chr. Hansen Holding A/S (CPSE:CHR).

Returns On Capital At Novozymes (CPH:NZYM B) Paint A Concerning Picture

Less than half of directors are independent

Third quarter 2022 earnings: Revenues in line with analyst expectations

Novozymes A/S Provides Earnings Guidance for the Year 2022

Biotalys Nv and Novozymes A/S Announces Successful Evoca™ Feasibility Study

A Look At The Intrinsic Value Of Novozymes A/S (CPH:NZYM B)

Novozymes A/S to Report Q3, 2022 Results on Nov 03, 2022

Now 21% undervalued after recent price drop

Now 20% undervalued after recent price drop

These 4 Measures Indicate That Novozymes (CPH:NZYM B) Is Using Debt Reasonably Well

The Returns On Capital At Novozymes (CPH:NZYM B) Don't Inspire Confidence

Consensus EPS estimates increase by 11%

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Novozymes A/S Provides Earnings Guidance for the Year 2022

Estimating The Fair Value Of Novozymes A/S (CPH:NZYM B)